NVO - Novo Nordisk A/S

NYSE - NYSE Delayed Price. Currency in USD
49.18
+0.97 (+2.01%)
At close: 4:02PM EDT

49.18 0.00 (0.00%)
After hours: 4:14PM EDT

Stock chart is not supported by your current browser
Previous Close48.21
Open49.41
Bid47.51 x 800
Ask49.25 x 38500
Day's Range48.83 - 49.43
52 Week Range44.28 - 58.37
Volume2,599,592
Avg. Volume1,567,879
Market Cap122.332B
Beta0.85
PE Ratio (TTM)19.70
EPS (TTM)2.50
Earnings DateN/A
Forward Dividend & Yield1.28 (2.65%)
Ex-Dividend Date2018-03-23
1y Target Est60.40
Trade prices are not sourced from all markets
  • Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin
    Zacksyesterday

    Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin

    Novo Nordisk A/S (NVO) acquires Ziylo Ltd. to speed up the development of glucose responsive insulins in a deal that could exceed $800 million.

  • Financial Times5 days ago

    [$$] Novo Nordisk buys UK university biotech spin-out Ziylo

    Novo Nordisk of Denmark, the world’s largest manufacturer of diabetes medicines, has bought Ziylo, a small UK biotech company spun out of the University of Bristol, in an unusual deal that both parties said could eventually be worth more than $800m if a series of milestones are met. Novo Nordisk sees Ziylo’s technology as the path to success in a “key strategic area”: the development of “glucose responsive insulins” whose activity depends on the amount of sugar in the patient’s bloodstream. This control would prevent hypoglycaemia, caused by a dangerous fall in blood glucose level, which is the main risk associated with insulin therapy for diabetes.

  • Novo Nordisk’s Biopharmaceuticals Segment: An Update
    Market Realist6 days ago

    Novo Nordisk’s Biopharmaceuticals Segment: An Update

    Novo Nordisk’s (NVO) biopharmaceuticals segment generated revenues of 4.4 billion Danish kroner in the second quarter of 2018, a ~4% YoY (year-over-year) decline in local currencies.

  • Analysts’ Recommendations for GlaxoSmithKline Stock
    Market Realist6 days ago

    Analysts’ Recommendations for GlaxoSmithKline Stock

    This year, analysts expect GlaxoSmithKline’s (GSK) revenue to grow 0.4% YoY (year-over-year) to ~30.3 billion British pounds from ~30.2 billion pounds, and its income margin to narrow YoY to 17.9% from 18.1%. They expect it to report EPS of 110.75 pence.

  • Novo Nordisk's Pricing Pressures Aren't Going Away
    Motley Fool7 days ago

    Novo Nordisk's Pricing Pressures Aren't Going Away

    Payers continue to seek lower drug prices from the diabetes expert.

  • A Look at Novo Nordisk’s Human Insulin and Obesity Business
    Market Realist7 days ago

    A Look at Novo Nordisk’s Human Insulin and Obesity Business

    In the first half of 2018, Novo Nordisk’s (NVO) human insulin generated revenues of 4.7 billion Danish kroner, a ~1% YoY (year-over-year) growth in local currencies.

  • How Novo Nordisk’s Premix Insulin Is Positioned after H1 2018
    Market Realist7 days ago

    How Novo Nordisk’s Premix Insulin Is Positioned after H1 2018

    Novo Nordisk’s (NVO) premix insulin segment witnessed a ~1% YoY (year-over-year) growth in local currencies in the first half of 2018 to 5.2 billion Danish kroner. That included revenues of 688 million Danish kroner, 856 million Danish kroner, 1.3 billion Danish kroner, and 1.9 billion Danish kroner in the United States, Europe, AAMEO (Africa, Asia, the Middle East, and Oceania), and China, respectively.

  • What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2
    Market Realist7 days ago

    What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products. In the second quarter, the segment’s revenue grew 3% YoY (year-over-year) at constant exchange rates to ~1.8 billion British pounds, as shown in the chart below. GlaxoSmithKline bought out Novartis’s (NVS) stake in the companies’ consumer healthcare joint venture on June 1.

  • Novo Nordisk’s Fast-Acting Insulins: A Performance Overview
    Market Realist7 days ago

    Novo Nordisk’s Fast-Acting Insulins: A Performance Overview

    In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, reflecting a ~2% YoY (year-over-year) growth in local currencies.

  • Can Victoza Continue to Boost Novo Nordisk’s Revenue Growth?
    Market Realist8 days ago

    Can Victoza Continue to Boost Novo Nordisk’s Revenue Growth?

    Novo Nordisk’s (NVO) Victoza generated revenues of 11.7 billion Danish kroner in the first half of 2018 compared to 11.5 billion Danish kroner in the first half of 2017, a ~2% YoY (year-over-year) growth and a ~12% YoY growth in local currencies.

  • Novo Nordisk: A Financial Overview after the First Half of 2018
    Market Realist8 days ago

    Novo Nordisk: A Financial Overview after the First Half of 2018

    Novo Nordisk (NVO) reported net revenues of 54.3 billion Danish kroner in the first half of 2018 compared to 57.1 billion Danish kroner in H1 2017. That’s a ~5% YoY (year-over-year) decline.

  • The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
    Zacks8 days ago

    The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

    The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

  • Novo Nordisk (NVO) Q2 2018 Earnings Conference Call Transcript
    Motley Fool11 days ago

    Novo Nordisk (NVO) Q2 2018 Earnings Conference Call Transcript

    NVO earnings call for the period ending June 30, 2018.

  • Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus
    Zacks11 days ago

    Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus

    Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.

  • Eli Lilly Stock History
    Motley Fool11 days ago

    Eli Lilly Stock History

    Here's how this company became a biopharma giant, and what could be in store next for investors.

  • Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates
    Zacks13 days ago

    Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates

    Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.

  • The Wall Street Journal14 days ago

    [$$] European Corporate Roundup for Wednesday

    It’s a busy day for earnings in Europe and Glencore notches a record profit on commodities recovery.

  • Associated Press14 days ago

    Novo Nordisk: 2Q Earnings Snapshot

    On a per-share basis, the Bagsvaerd, Denmark-based company said it had profit of 68 cents. The drugmaker posted revenue of $4.39 billion in the period. Novo Nordisk shares have declined slightly more than ...

  • Novo Nordisk CEO Sees Demand for Better Products
    Bloomberg14 days ago

    Novo Nordisk CEO Sees Demand for Better Products

    Lars Fruergaard Jorgensen, chief executive officer at Novo Nordisk, discusses the market reaction to earnings, drug prices in the U.S. and their M&A prospects. He speaks on "Bloomberg Markets: European ...

  • Financial Times14 days ago

    [$$] Shares in Novo Nordisk fall after warning on US price cuts

    The Danish pharma group is facing intensifying competition over prices — particularly in the US — and while negotiations with pharmacy benefit managers and managed care organisations were progressing, it expected average prices after rebates “to be lower compared with the levels in 2018”. Lars Fruergaard Jorgensen, chief executive, said sales growth in the first half of 2018 had been driven by “solid performance of our key innovative products” — Saxenda for obesity and Victoza, Tresiba and Xultophy for diabetes.

  • BMY vs. NVO: Which Stock Is the Better Value Option?
    Zacks14 days ago

    BMY vs. NVO: Which Stock Is the Better Value Option?

    BMY vs. NVO: Which Stock Is the Better Value Option?

  • Analysts’ Recommendations for Sanofi Stock before Q2 Results
    Market Realist26 days ago

    Analysts’ Recommendations for Sanofi Stock before Q2 Results

    Sanofi (SNY) is scheduled to announce its earnings results for the second quarter of fiscal 2018 on July 31. The company is a global pharmaceuticals player with products and therapies across the specialty areas of oncology, immunology, vaccines, multiple sclerosis, rare disease disorders, neurology, cardiovascular diseases, diabetes, and infectious diseases. As of July 25, according to a recent Reuters survey, two of the five analysts covering SNY stock have given it a “strong buy” recommendation, and three have rated it a “hold.” There are no “sell” ratings.

  • Novartis’s Key Developments in July
    Market Realist28 days ago

    Novartis’s Key Developments in July

    As we’ve already seen, Novartis (NVS) reported a 7% growth in operating revenues to ~$13.16 billion in Q2 2018. That compares to revenues of ~$12.24 billion in Q2 2017.

  • Amazon, Novo Nordisk and Tesla are the Yahoo Finance charts of the day.
    Yahoo Finance Video13 days ago

    Amazon, Novo Nordisk and Tesla are the Yahoo Finance charts of the day.

    Let's check out the Yahoo Finance charts of the day. Amazon  (AMZN): Shares are up in early trade, at around .25%.  Amazon is adding a curbside pickup option at Whole Foods for Prime members. Shoppers will be able to order milk, eggs and other groceries on the Prime Now app and park in reserved spaces where workers will place the items in their cars. Novo Nordisk (NVO): Shares down here at 5.34%.  The Danish pharmaceutical company reported profit in line with forecasts for the second quarter, but the company said prices in the U.S, market would be lower next year. Tesla (TSLA): Shares down here, at around .68%. Tesla is on watch following Elon Musk's tweet Tuesday about possible plans to take the company private and reports of a $2 billion dollar investment in the Saudi Arabia investment fund. Members of the Tesla board said they have met "several times" to discuss Musk's desire to go private. For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.

  • Novo Nordisk CEO Sees Demand for Better Products
    Bloomberg Video14 days ago

    Novo Nordisk CEO Sees Demand for Better Products

    Aug.08 -- Lars Fruergaard Jorgensen, chief executive officer at Novo Nordisk, discusses the market reaction to earnings, drug prices in the U.S. and their M&A prospects. He speaks on "Bloomberg Markets: European Open."